FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response	s)															
1. Name and Address of Reporting Person * DELUCCA JOHN				2. Issuer Name and Ticker or Trading Symbol ENZO BIOCHEM INC [ENZ]							mbol	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner					
(Last) (First) (Middle) C/O ENZO BIOCHEM, INC., 527 MADISON AVENUE				3. Date of Earliest Transaction (Month/Day/Year) 01/23/2007							y/Year)	Office	r (give title belo	ow)	Other (specify	below)	
NEW YORK, NY 10022				4. If Amendment, Date Original Filed(Month/Day/Year)						6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting PersonForm filed by More than One Reporting Person							
(City) (State) (Zip)				Table I - Non-Derivative Securities Acqu						ired, Disposed of, or Beneficially Owned							
1.Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year			Exec	Deemed ution Date, if	(Instr. 8)		(A) or Disp		Disposed	of (D)	Beneficially Owned Fo Reported Transaction(s		ollowing	Form:	7. Nature of Indirect Beneficial		
				(Mor	Month/Day/Year)			ode	V	Amour	(A) or (D)	Price	(Instr. 3 a	3 and 4)		Direct (D) or Indirect (I) (Instr. 4)	Ownership (Instr. 4)
Restricted Stock Units (1) 01/23/2007						A		7,000	A	<u>(1)</u>	82,824	82,824 (2)		D			
			Table II -					quire	conta the fo	ained in orm dis	n this for splays a	m are curre eficial	e not requ ntly valid	ction of inf uired to res OMB conf	spond unle	ess	C 1474 (9-02)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		Execution Da any	4. Transaction Code Year) (Instr. 8)		5.		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. T Am Und Sec	Fitle and ount of derlying urities tr. 3 and	Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)	Owner Form of Deriva Securit Direct or Indi	Beneficia Ownershi y: (Instr. 4)		
					Code	V	(A)	(D)	Date Exerc		Expiration Date	n Title	Amount or Number of Shares				

Reporting Owners

	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
DELUCCA JOHN C/O ENZO BIOCHEM, INC. 527 MADISON AVENUE NEW YORK, NY 10022	X						

Signatures

/s/ John DeLucca	01/23/2007
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- On January 23, 2007, the Reporting Person was granted 7,000 Restricted Stock Units as compensation for serving as an independent director of the Issuer. Each Restricted (1) Stock Unit consists of a right to the issuance of one share of common stock, par value \$.01 ("Common Stock"). The Restricted Stock Units are subject to a two-year vesting period.
- (2) As of the date hereof, the Reporting Person has a direct beneficial ownership interest in: (a) 2,500 shares of Common Stock; and (b) stock options to purchase 80,324 shares of Common Stock. The Reporting Person also owns 9,500 Restricted Stock Units that will not vest within the next 60 days.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.